然而，在临床中，仍有近三成的病人使用了目前国际上最先进的分子靶向治疗药物却没有效果。
However, in clinical practice, there are still Jinsan Cheng patients to use the current world's most advanced molecular targeted therapies have no effect.
Lapatinib是一种分子药物市场蓬勃发展的产品——被设计用来靶向治疗与疾病相关的特定的蛋白质分子。
Lapatinib is a product of the growing field of molecular medicine-the design of drugs to attack specific protein molecules associated with particular diseases.
虽然IPA - 3本身可能不适合人类使用的药物，但这种分子可以形成一个新的靶向治疗的理论基础。
While IPA-3 itself might not be a suitable as a drug for use in humans, the molecule could form the conceptual basis of a new targeted therapeutic.
应用伊马替尼对包含该突变体的肿瘤进行分子靶向治疗，多数患者表现为药物抵抗。
The most GISTs are drug-resistant when be treated with imatinib which is a molecular targeted drug.
近年来国际上对其治疗的研究已主要集中在分子水平上，如抗肿瘤坏死因子（TNF） 抗体，T细胞靶向药物等。
Recently some new medicines as anti-TNF bodies and T cell directed agents are used in treatment.
肺癌分子靶向治疗近年来取得较大进展，特别是针对表皮生长因子受体(EGFR)分子靶向药物表现出确定的临床效果。
Molecular targeted therapy has a advance development, the molecular targeted therapies drug for epidermal growth factor receptor (EGFR) present definite clinic effect.
因此，分子靶向药物导向治疗有望成为治疗结直肠癌的有效手段。
Therefore, the molecular targeted drug and treatment of colorectal cancer is expected to become an effective means of treatment.
因此，分子靶向药物导向治疗有望成为治疗结直肠癌的有效手段。
Therefore, the molecular targeted drug and treatment of colorectal cancer is expected to become an effective means of treatment.
应用推荐